Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with AML.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
  • Plan evidence-based therapeutic strategies for older unfit patients, those with preexisting comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
  • Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations or positive for CD33
  • Assess the available evidence to optimally integrate immunotherapeutic agents, including monoclonal antibody–based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell–based therapy
  • Address patient-specific challenges surrounding pre- and posttransplant processes and novel agents to mitigate risk
  • Manage treatment-related toxicities associated with novel therapeutics
Additional information
Supporters: 

Supported by an independent educational grant from AbbVie
Supported by an independent medical education grant from Bristol Myers Squibb
Supported by an educational grant from Genentech, a member of the Roche Group

Course summary
Available credit: 
  • 2.50 AAPA Category 1 CME credit
  • 2.50 ACPE contact hours
  • 2.50 AMA PRA Category 1 Credit™
  • 2.50 ANCC contact hours
  • 2.50 Participation
Course opens: 
12/23/2021
Course expires: 
12/23/2022
Cost:
$0.00

Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel A. Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Eunice S. Wang, MD
Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Amir T. Fathi, MD
Abbvie, Inc.: Consulting Fee; Grant/Research Support 
Agios, Inc.: Consulting Fee; Grant/Research Support
Astellas Pharma US, Inc.: Consulting Fee 
Blueprint Medicines: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Foghorn Therapeutics: Consulting Fee
Genentech, Inc.: Consulting Fee
Kite Pharma: Consulting Fee
Kura Oncology, Inc.: Consulting Fee
MorphoSys AG: Consulting Fee 
Pfizer Inc.: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee 
Trillium Therapeutics Inc.: Consulting Fee

Daniel A. Pollyea, MD, MS
Abbvie, Inc.: Consulting Fee; Grant/Research Support 
Aprea Therapeutics: Consulting Fee
Arcellx, Inc.: Consulting Fee
Astellas Pharma US, Inc.: Consulting Fee
BeiGene: Consulting Fee
BerGenBio: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support 
Celgene Corporation: Consulting Fee
Foghorn Therapeutics: Consulting Fee
Genentech, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Jazz Pharmaceuticals Inc.: Consulting Fee 
Karyopharm Therapeutics: Consulting Fee; Grant/Research Support 
Novartis Pharmaceuticals Corporation: Consulting Fee
Syndax Pharmaceuticals Inc.: Consulting Fee
Syros Pharmaceuticals: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee
Teva Pharmaceutical Industries Ltd: Grant/Research Support

Eunice S. Wang, MD
Abbvie, Inc./Genentech, Inc.: Consulting Fee 
Astellas Pharma US, Inc./Jazz Pharmaceuticals Inc.: Consulting Fee 
Bristol-Myers Squibb Company/Celgene Corporation/Kite Pharma: Consulting Fee
DAVA Oncology: Honoraria
Gilead Sciences, Inc.: Consulting Fee
GlaxoSmithKline: Consulting Fee
Kura Oncology, Inc.: Consulting Fee; Honoraria
Mana Therapeutics: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee; Honoraria
Rafael Pharmaceuticals, Inc.: Consulting Fee
Stemline Therapeutics, Inc.: Consulting Fee; Honoraria
Takeda Pharmaceuticals North America, Inc.: Consulting Fee 

NCCN and CCO Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 2.5 contact hours.

Pharmacists
NCCN designates this application-based continuing education activity for 2.5 contact hours (0.25 CEUs) of continuing education credit. UAN: JA4008196-0000-21-138-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.5 AAPA Category 1 CME credits. Approval is valid until December 23, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 2.50 AAPA Category 1 CME credit
  • 2.50 ACPE contact hours
  • 2.50 AMA PRA Category 1 Credit™
  • 2.50 ANCC contact hours
  • 2.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing